Literature DB >> 9769291

Inspiratory muscle function and body composition in cystic fibrosis.

A A Ionescu1, K Chatham, C A Davies, L S Nixon, S Enright, D J Shale.   

Abstract

Loss of body mass, which occurs in the later stages of cystic fibrosis (CF), probably affects all body compartments. We hypothesized that loss of skeletal muscle mass would include inspiratory muscles and impair their function. To test this, we determined the effect of body mass index (BMI) and lean body mass (LBM) depletion on handgrip (HG) force and inspiratory muscle function (IMF). The maximum inspiratory pressure (MIP) and the sustained maximum inspiratory pressure (SMIP) were measured with a computerized system. The relationship of IMF and reduced BMI to survival was studied in 49 patients, and a further 25 patients were studied to define the link between IMF and LBM. LBM was assessed by anthropometry. In the survival study a BMI < 20 kg/m2 was associated with a low SMIP (p < 0.001) and reduced survival, whereas MIP was relatively preserved. In the cross-sectional study SMIP (p < 0.001), MIP (p < 0.01), and HG (p < 0.01) were all reduced in the low LBM group, but not when related to total LBM. C-reactive protein and LBM were inversely related (r = -0.71, p < 0.01). Impaired IMF was chiefly a loss of sustained muscle contraction secondary to a reduced skeletal muscle mass, which may be related to pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769291     DOI: 10.1164/ajrccm.158.4.9710079

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

1.  Manifesting carriage of a Duchenne muscular dystrophy mutation: an unusual cause of impaired lung function in CF.

Authors:  Woolf Walker; Gary Connett
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

Review 2.  Inspiratory muscle training in heart disease and heart failure: a review of the literature with a focus on method of training and outcomes.

Authors:  Lawrence P Cahalin; Ross Arena; Marco Guazzi; Jonathan Myers; Gerson Cipriano; Gaspar Chiappa; Carl J Lavie; Daniel E Forman
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-02

Review 3.  Frailty in Pulmonary and Critical Care Medicine.

Authors:  Jonathan P Singer; David J Lederer; Matthew R Baldwin
Journal:  Ann Am Thorac Soc       Date:  2016-08

4.  Respiratory muscle strength and the risk of incident cardiovascular events.

Authors:  J van der Palen; T D Rea; T A Manolio; T Lumley; A B Newman; R P Tracy; P L Enright; B M Psaty
Journal:  Thorax       Date:  2004-12       Impact factor: 9.139

5.  Altered tissue distribution in adults with cystic fibrosis.

Authors:  C E Bolton; A A Ionescu; W D Evans; R J Pettit; D J Shale
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 6.  Growth hormone and exercise tolerance in patients with cystic fibrosis.

Authors:  Matthias Hütler; Ralph Beneke
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

7.  Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; J C Souberbielle; I Azhar; J C Ruiz; P Magnine; V Colomb; C Le Bihan; D Folio; G Lenoir
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

8.  Deficits in bone mineral content in children and adolescents with cystic fibrosis are related to height deficits.

Authors:  Andrea Kelly; Joan I Schall; Virginia A Stallings; Babette S Zemel
Journal:  J Clin Densitom       Date:  2008-08-30       Impact factor: 2.617

9.  Body composition and pulmonary function in cystic fibrosis.

Authors:  Saba Sheikh; Babette S Zemel; Virginia A Stallings; Ronald C Rubenstein; Andrea Kelly
Journal:  Front Pediatr       Date:  2014-04-15       Impact factor: 3.418

10.  Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study.

Authors:  Doug L Forrester; Alan J Knox; Alan R Smyth; Andrew W Fogarty
Journal:  J Cyst Fibros       Date:  2012-09-05       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.